Ashleigh Butts-Wilkerson, MD
Family Medicine · Mobile, ALNPI 1609136787
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $47,292 of the $53,607 with a category attached, or 88.2%. Organon accounts for 84.9% of it on its own, with 34 other manufacturers making up the rest. Reporting peaked in 2021 at $23,537 and has fallen 82.0% since, to $4,244 in 2025. Among family medicine clinicians in AL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 371 payments — averaging $144.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Organon$45K
- Merck$4K
- Novo Nordisk$763
- AbbVie$702
- Johnson & Johnson$406
- AstraZeneca$370
- plus $2K from 29 others
What the payments were for
- Speaking & faculty fees$47,29288%
- Travel & lodging$1,6683%
- Food & beverage$4,4568%
- Education$1910%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Organon | 44 | $45,489 |
| Merck | 5 | $3,582 |
| Novo Nordisk | 61 | $763 |
| AbbVie | 58 | $702 |
| Johnson & Johnson | 43 | $406 |
| AstraZeneca | 16 | $370 |
| Amgen(2 entities) | 31 | $346 |
| Astellas Pharma US Inc | 4 | $203 |
| Bayer | 13 | $186 |
| Novartis | 12 | $183 |
| Sumitomo Pharma America, Inc. | 12 | $166 |
| Lilly USA, LLC | 10 | $143 |
| Pfizer | 8 | $137 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 7 | $134 |
| GSK | 8 | $128 |
| Dexcom, Inc. | 4 | $86 |
| Phathom Pharmaceuticals, Inc. | 4 | $74 |
| Esperion Therapeutics, Inc. | 5 | $72 |
| Abbott | 3 | $57 |
| Boehringer Ingelheim | 3 | $44 |
| Currax Pharmaceuticals LLC | 2 | $37 |
| Supernus Pharmaceuticals, Inc. | 2 | $35 |
| Amarin Pharma, Inc. | 2 | $34 |
| Exact Sciences | 2 | $34 |
| Biohaven Pharmaceuticals, Inc. | 2 | $33 |
| Upsher-smith Laboratories LLC | 1 | $20 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $20 |
| Sanofi Pasteur Inc. | 1 | $17 |
| Gilead | 1 | $17 |
| Ironwood Pharmaceuticals, Inc | 1 | $16 |
| Corcept Therapeutics | 1 | $16 |
| Otsuka America Pharmaceutical, Inc. | 1 | $16 |
| Sunovion Pharmaceuticals Inc. | 1 | $14 |
| Idorsia Pharmaceuticals US Inc | 1 | $14 |
| Axsome Therapeutics, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$53,607 in reported general payments places this provider in the 95th percentile of 1,680 family medicine providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 155 | $210,857 |
| JardianceEmpagliflozin | 62 | $64,826 |
| EliquisApixaban | 59 | $59,483 |
| MounjaroTirzepatide | 30 | $39,539 |
| FarxigaDapagliflozin Propanediol | 49 | $39,483 |
| RybelsusSemaglutide | 11 | $29,967 |
| LinzessLinaclotide | 32 | $29,306 |
| MyrbetriqMirabegron | 25 | $25,878 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 30 | $21,570 |
| JanuviaSitagliptin Phosphate | 14 | $19,166 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 31 | $12,354 |
| Repatha SureclickEvolocumab | 12 | $11,265 |
| TrulicityDulaglutide | 11 | $10,824 |
| EntrestoSacubitril/Valsartan | 13 | $10,270 |
| Breo ElliptaFluticasone/Vilanterol | 13 | $8,064 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Xultophy 100-3.6 | $763 | $246,085179 claims |
| Boehringer IngelheimJardiance, Synjardy Xr, Spiriva Respimat | $44 | $78,80487 claims |
| PfizerEliquis | $137 | $59,48359 claims |
| Lilly USA, LLCMounjaro, Trulicity | $143 | $50,36341 claims |
| AstraZenecaFarxiga | $370 | $39,48349 claims |
| AbbVieLinzess, Synthroid | $702 | $33,11072 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $128 | $29,63443 claims |
| Astellas Pharma US IncMyrbetriq | $203 | $25,87825 claims |
| MerckJanuvia | $3,582 | $19,16614 claims |
| NovartisEntresto | $183 | $10,27013 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,680 family medicine providers in Alabama.
Other family medicine in Mobile
- Joel LaughlinMobile$75K
- Anthony NguyenMobile$20K
- Mark WilesMobile$14K
- Lashelle BarmoreBirmingham$486K
- Regina BenjaminBayou la Batre$222K
- Jonathan ParkerMuscle Shoals$214K
- Kathleen DupperHuntsville$210K
- Whitney TewHuntsville$114K
- Kelly HunterTuscaloosa$84K
- Daniel EnglertHuntsville$82K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.